Tariffs imposed on medical supplies have significantly impacted and will continue to impact the healthcare industry, affecting pricing, availability, and reliability of essential medical goods.

The National Institutes of Health’s (NIH) recent decision to cap indirect costs at 15 percent has created significant concern within the healthcare and research sectors.

A PBM is a key player in the pharmaceutical supply chain, responsible for administering prescription drug benefit plans by managing relationships, networks, claims, formularies, rebates, and cost-saving or outcome-improving services for clients.

The Department of Justice and seventeen states retained BRG in an antitrust action against Google in which they claimed that Google monopolized three digital advertising technology markets.